FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number: 3235-028											
Estimated average burden											
hours per response.	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

- ,	d Address		*		2 199	suer Na	me ar	nd Tic	ker or T	radino	Symbol			5 Rela	ationshir	of Reportin	na Per	son(s) to Is	suer
Name and Address of Reporting Person' Bellon Christine					2. Issuer Name and Ticker or Trading Symbol Beam Therapeutics Inc. [BEAM]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
<u>Bellon Christine</u>															Office	tor er (give title		10% Ov Other (s	
(Last)	3. Da	Date of Earliest Transaction (Month/Day/Year)								1	below			below)	Specify				
(Last) (First) (Middle) C/O BEAM THERAPEUTICS INC.,						01/02/2025								Chief Legal Officer					
238 MAIN STREET																			
230 WAIN STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)							6	6. Individual or Joint/Group Filing (Check Applicable						
(Street)						and the state of original riled (Montal Buy rour)								Line)					
CAMBRIDGE MA 02142													1	Form filed by One Reporting Person					
															Perso	filed by Mo	re thai	n One Repo	orting
(City)	(State) (Zip)																
		Table	1 - No	on-Deriva	tive	Secui	rities	Acc	uirec	d. Dis	posed of	or B	enefic	cially	Own	ed			
1. Title of S	Security (Ir			2. Transacti					3. 4. Securities Acquired (A)								6. Ownership		7. Nature
	, , , , , , , , , , , , , , , , , , ,			Date (Month/Day)	(Year)	Execution Date,			Transaction Code (Instr. 3, 4			str. 3, 4 a	and 5) Securit		ties Fo		orm: Direct	of Indirect Beneficial	
\ \frac{1}{2}						(Month/Day/Year)		8)							Owned Following Reported		nstr. 4)	Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price		Transa	action(s) 3 and 4)			(
Common Stock 01/02/20						25			S ⁽¹⁾		1,241	D	\$24.	\$24.68(2)		02,968		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
	(e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Conversion Date Executor Date or Exercise (Month/Day/Year) if any				saction of Deriv Secu Acqu (A) o Dispo		r osed) r. 3, 4	Expiration I (Month/Day		ate	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sed (Ins	Price of rivative curity str. 5)	tive derivative ity Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$24.21 to \$25.02, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

By: /s/ Christine Bellon

** Signature of Reporting Person Date

01/06/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.